Abstract 726P
Background
Patients with recurrent cervical cancer, especially those resistant to platinum-based chemotherapy, have limited treatment options. PD-1 blockade monotherapy stands out as one of the optimal choices in this context. PARP inhibition may exert an immune modulatory effect through the cGAS/STING pathway, and this phase II trial aims to explore the efficacy and safety of pembrolizumab (Pem) plus olaparib (Ola) in this patient cohort.
Methods
This multicenter investigator-initiated single-arm Phase II trial assesses the antitumor effects and survival outcomes of combining PD-1 inhibition with Pem and PARP inhibition with Ola. Eligible patients, who had prior platinum-based chemotherapies and no prior immunotherapy, received Pem (200mg every 3 weeks) and Ola (600mg per day) combination therapy until disease progression or unacceptable toxicity. The primary endpoint is objective response rate (ORR) by RECISTv1.1.
Results
Between June 2021 and July 2022, twenty-eight patients were enrolled. Patient characteristics included a median age of 55 years, with 14 (50%) patients having squamous cell carcinoma and 14 (50%) adenocarcinoma/adenosquamous carcinoma. Twenty-two (79%) patients had more than 2 lines of chemotherapy, and 22 (79%) patients had a history of bevacizumab. Twenty-six of 28 patients were evaluable for antitumor activity, as two patients did not have RECIST evaluation after treatment initiation. The ORR was 7.7% and the disease control rate was 53.8%. The median PFS and OS were 3.4 and 11.9 months, respectively. No patients required Pem discontinuation, but 4 (14%) patients required Ola discontinuation due to adverse events (AEs). All patients and 21 (75%) patients experienced any grade of AEs due to Ola or Pem, respectively. Grade≥3 AEs were observed in 17 (61%) patients, with anemia (29%) and decreased white blood cell counts (11%) being the most common.
Conclusions
This trial investigates Pem plus Ola combination therapy in platinum-experienced recurrent cervical cancer, revealing manageable safety. However, limited activity was observed with the addition of Ola to PD-1 inhibition in this study.
Clinical trial identification
NCT04641728. First posted November 24, 2020.
Editorial acknowledgement
Legal entity responsible for the study
Gynecologic Oncology Trial and Investigation Consortium (GOTIC).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733P - Efficacy and safety of sacituzumab govitecan (SG) in patients with advanced/metastatic endometrial cancer (EC): Updated results from TROPiCS-03
Presenter: Bradley Corr
Session: Poster session 01
734P - Impact of investigator-assessed response on overall survival (OS) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) in the ENGOT-EN6-NSGO/GOG3031/RUBY trial
Presenter: Cara Mathews
Session: Poster session 01
735P - HRD signature (HRDsig) in endometrial cancer (EC)
Presenter: Bhavana Pothuri
Session: Poster session 01
736P - Exceptional clinical benefit (ECB) from immune checkpoint inhibitors (ICIs) in mismatch-repair deficient (MMRd) in recurrent /metastatic endometrial cancer (r/mEC): Are we curing a subset of MMRd EC patients (pts)?
Presenter: Juan Francisco Grau Béjar
Session: Poster session 01
737P - Characterization of tumor response with lenvatinib plus pembrolizumab (LEN + Pembro) in the ENGOT-en9/LEAP-001 study
Presenter: Anna Danska-Bidzinska
Session: Poster session 01
739P - Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA)
Presenter: Whitney Grither
Session: Poster session 01
740P - A monocentric analysis of ESCAT gene actionability detection in non-specific molecular profile (NSMP) early-stage endometrial cancer
Presenter: Luca Mastrantoni
Session: Poster session 01
741P - Comparison of the Idylla microsatellite instability (MSI) test with a gold standard MSI test and mismatch repair immunohistochemistry in endometrial cancer
Presenter: Ramona Erber
Session: Poster session 01
743P - Immunotherapy plus chemotherapy in the first-line treatment for primary advanced or recurrent endometrial cancer: An extracted individual patient data and trial-level meta-analysis
Presenter: Mariana Gouveia
Session: Poster session 01